Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote - NPR — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA advisers will vote on whether to recommend a multi-cancer blood test for approval, with NPR framing it as a pivotal recommendation decision.
- Grail's cancer test screens for 50 cancers, and whether Medicare and other health insurers cover it depends on FDA approval, per MarketWatch.
- GRAL stock clocked its best day in over 1.5 [years], reflecting investor reaction to the FDA advisory committee vote.
Why it matters: An FDA advisory recommendation on a 50-cancer screening test would set the regulatory tone for next-generation liquid-biopsy diagnostics; Medicare coverage is the commercial gateway, meaning an approval path directly determines whether insurers pay for early detection across dozens of cancers at once.
Ask SkimNews
